Scheme:
Patients will receive different chemotherapy regimens depending on the pathological type.
Squamous cell carcinoma:Docetaxel/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Docetaxel/Cisplatin 2 cycles.
Non-squamous cell carcinoma:Pemetrexed/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Pemetrexed/Cisplatin 2 cycles.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18≤Age≤65;
ECOG performance status of 0 or 1;
Pathological diagnosis with Stage IIIA-N2 NSCLC which is clinically resectable and the N2 is diagnosed by either mediastinoscopy,EBUS,PET/CT;
WBC≥4.0×109/l, ANC≥1.5×109/l, PLT≥100.0×109/l, Hb≥90g/l;hepatorenal function is normal;
Without a history of other malignancies before enrollment, except for non-melanoma skin cancer, in situ cervical cancer;
The patient can understand the research and sign the informed consent.
You may not be if
Female in pregnancy or lactating;Female of childbearing age without contraception;
With acute infection or other serious underlying disease;
With a significant history of neurological of psychiatric disease,including the dementia which may affect the ability to understand and sign the informed consent;
Have received other treatment within the last 30 days before enrollment;
With uncontrollable diabetes(blood glucose is unstable after treatment or FBG≥8mol/L).